

Item 8.01 Other Events

On December 28, 2012, Emergent BioSolutions Inc. issued a press release announcing that it has entered into a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the United States. This license enables Emergent to fulfill the requirement to secure a pandemic influenza vaccine candidate under its contract with the Biomedical Advanced Research and Development Authority, which established Emergent as a Center for Innovation in Advanced Development and Manufacturing in June 2012. A copy of the press release is attached as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99 Press release issued by the company on December 28, 2012.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 28, 2012 EMERGENT
BIOSOLUTIONS
INC.
By: /s/ Jay G. Reilly
Jay G. Reilly
General Counsel

Exhibit Index

99 Press release issued by the company on December 28, 2012.